Benefits and harms of Sodium-Glucose co-Transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and Meta-Analysis

PLoS ONE

Volumn 11, Issue 11, 2016, Pages

  Storgaard, Heidi ^a   Gluud, Lise L ^b   Bennett, Cathy ^c   Grøndahl, Magnus F ^a   Christensen, Mikkel B ^a   Knop, Filip K ^a,d,e   Vilsbøll, Tina ^a,d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c Institute for Clean Growth and Future Mobility   (United Kingdom)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CANAGLIFLOZIN; CREATININE; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

ADVERSE OUTCOME; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIET RESTRICTION; DISEASE SEVERITY; DRUG RESPONSE; DRUG SAFETY; GENITAL TRACT INFECTION; HEART RATE; HUMAN; HYPOGLYCEMIA; KETOACIDOSIS; LIVER FUNCTION TEST; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84994731812     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0166125     Document Type: Article

References (111)

1. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014; 383(9922):1068-83. doi: 10.1016/S0140-6736(13) 62154-6 PMID: 24315620
2. Gaede P, Vedel P, Larsen N, Jensen GVH, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348:383-93. doi: 10. 1056/NEJMoa021778 PMID: 12556541
3. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMID: 10938048
4. FDA. Briefing document NDA 204042 Invokana (canagliflozin) tablets. 2013.
5. FDA. Briefing document NDA 202293: Dapagliflozin oral tablets, 5 and 10mg. 2013.
6. FDA. Jardiance (empagliflozin) press release. 2014.
7. EMA. Assessment report, canagliflozin EMA/718531/2013. 2013.
8. EMA. Jardiance (empagliflozin): assessment report; procedure No. EMEA/H/C/002677/0000. 2014.
9. EMA. Jardiance (empagliflozin): procedure No. EMEA/H/C/002677/0000 (Annex 1). 2014.
10. EMA. European Medicines Agency Assessment Report: Dapagliflozin (Forxiga). 2015.
11. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8(8):495-502. doi: 10.1038/nrendo.2011.243 PMID: 22310849
12. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care. 2010; 33(10):2217-24. doi: 10.2337/dc10-0612 PMID: 20566676
13. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013; 36(11):3396-404. doi: 10.2337/dc12-2673 PMID: 23963895
14. Haering HU, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015; 110 (1):82-90. doi: 10.1016/j.diabres.2015.05.044 PMID: 26324220
15. Kovacs CS, Seshiah V, Merker L, Christiansen AV, Roux F, Salsali A, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther. 2015; 37(8):1773-88 e1. doi: 10.1016/j.clinthera.2015.05.511 PMID: 26138864
16. Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2014; 16 (2):147-58. doi: 10.1111/dom.12188 PMID: 23906415
17. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35(6):1232-8. doi: 10.2337/dc11-1926 PMID: 22492586
18. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, Dapagliflozin 006 Study G. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014; 16(2):124-36. doi: 10.1111/dom.12187 PMID: 23911013
19. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012; 156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003 PMID: 22431673
20. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140-9. doi: 10.2337/dc14-2441 PMID: 25538310
21. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22):2117-28. doi: 10.1056/ NEJMoa1504720 PMID: 26378978
22. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J. 2013; 166(2):217-23 e11. doi: 10.1016/j.ahj.2013.05.007 PMID: 23895803
23. Raz I, Wiviott S. Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58): NCT01730534: AstraZeneca. 2016.
24. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014; 8(4):262-75 e9. doi: 10.1016/j.jash.2014.01.007 PMID: 24602971
25. Berhan A, Barker A. Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord. 2013; 13(1):58. doi: 10.1186/1472-6823-13-58 PMID: 24341330
26. Goring S, Hawkins N, Wygant G, Roudaut M, Townsend R, Wood I, et al. Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. Diabetes Obes Metab. 2014; 16(5):433-42. doi: 10.1111/dom.12239 PMID: 24237939
27. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014; 16(10):984-93. doi: 10.1111/dom.12307 PMID: 24766495
28. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012; 44(4):375-93. doi: 10.3109/07853890.2011.560181 PMID: 21495788
29. Singh AK, Singh R. Combination therapy of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences. Expert Rev Clin Pharmacol. 2016; 9 (2):229-40. doi: 10.1586/17512433.2016.1123616 PMID: 26589238
30. Sonesson C, Johansson PA, Johnsson E, Gause-Nilsson I. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol. 2016; 15(1):37. doi: 10.1186/s12933-016-0356-y PMID: 26895767
31. Triplitt C, Solis-Herrera C, Cersosimo E, Abdul-Ghani M, Defronzo RA. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2015; 16(18):2819-33. doi: 10.1517/14656566.2015.1114098 PMID: 26583910
32. Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013; 159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007 PMID: 24026259
33. Yoon J, Min SH, Hahn S, Cho YM. Indirect Comparison to Evaluate the Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors (DPP4I) and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2I) Added to Insulin Therapy in Type 2 Diabetes. Value Health. 2015; 18(7):A599. doi: 10.1016/j.jval.2015.09.2050 PMID: 26533362
34. Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes Obes Metab. 2016; 18(8):783-94. doi: 10.1111/dom.12670 PMID: 27059700
35. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstrom J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2016; 4(5):411-9. doi: 10.1016/S2213-8587(16)00052-8 PMID: 27009625
36. Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open. 2016; 6(2). doi: 10.1136/ bmjopen-2015-009417 PMID: 26911584
37. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. doi: 10.1056/NEJMoa0806470 PMID: 18784090
38. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360(2):129-39. doi: 10. 1056/NEJMoa0808431 PMID: 19092145
39. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358(24):2560-72. doi: 10.1056/NEJMoa0802987 PMID: 18539916
40. Storgaard H, Gluud LL, Christensen M, Knop FK, Vilsboll T. The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. BMJ Open. 2014; 4(8):e005378. doi: 10.1136/bmjopen-2014-005378 PMID: 25232561
41. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339.
42. Childers K. Additional data: HDL and triglyceride absolute changes of ALAT, LDL, and serum creatinine. Overall adverse events (all types) tables by System Organ Class (SOC), other adverse events including fractures: Janssen Pharmaceuticals Inc, a pharmaceutical company of Johnson & Johnson. 2014.
43. Lund S. Additional data: LDL, ALAT, serum creatinine, heart rate, systolic and diastolic blood pressure. Adverse events fractures, all cancers, bladder and breast cancer: Boehringer Ingelheim Pharma GmbH & Co. 2014.
44. Nahrebne K. Additional data CSRs: LDL given in percentage change from baseline, ALAT, serum creatinine, heart rate, systolic and diastolic blood pressure. Overall adverse events (all types) tables by System Organ Class (SOC), other adverse events including fractures: AstraZeneca Pharmaceuticals. 2014.
45. The YODA-project, Yale University (http://yoda.yale.edu/) [Internet]. 2014.
46. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
47. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4):383-94. doi: 10.1016/j.jclinepi.2010.04.026 PMID: 21195583
48. Schünemann H, Brozek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013.
49. Review Manager (RevMan) [Computer program]. 5.3.5 ed. Copenhagen: The Nordic Cochrane Centre The Cochrane Collaboration; 2014.
50. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12):2582-92. doi: 10. 1007/s00125-013-3039-1 PMID: 24026211
51. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009; 32(4):650-7. doi: 10.2337/dc08-1863 PMID: 19114612
52. Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013; 1(3):208-19. doi: 10.1016/s2213-8587(13)70084-6 PMID: 24622369
53. Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995). 2013; 41(2):72-84. doi: 10.3810/hp.2013.04.1020 PMID: 23680739
54. Bode B, Stenlof K, Harris S, Sullivan D, Fung A, Usiskin K, et al. Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes. Diabetes Obes Metab. 2015; 17(3):294-303. doi: 10.1111/dom.12428 PMID: 25495720
55. Forst T, Guthrie R, Goldenberg R, Yee J, Vijapurkar U, Meininger G, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab. 2014; 16(5):467-77. doi: 10.1111/dom.12273 PMID: 24528605
56. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab. 2013; 15(12):1136-45. doi: 10.1111/dom.12149 PMID: 23782594
57. Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013; 15(4):372-82. doi: 10.1111/dom.12054 PMID: 23279307
58. Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014; 30(2):163-75. doi: 10. 1185/03007995.2013.850066 PMID: 24073995
59. Wilding JP, Charpentier G, Hollander P, Gonzalez-Galvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013; 67(12):1267-82. doi: 10.1111/ijcp. 12322 PMID: 24118688
60. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375(9733):2223-33. doi: 10.1016/s0140-6736(10)60407-2 PMID: 20609968
61. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11(1):43. doi: 10.1186/1741-7015-11-43 PMID: 23425012
62. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11:193-.
63. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012; 97 (3):1020-31. doi: 10.1210/jc.2011-2260 PMID: 22238392
64. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014; 16(2):159-69. doi: 10.1111/dom.12189 PMID: 23906445
65. Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care. 2015; 38(7):1218-27. doi: 10.2337/dc14-0315 PMID: 25852208
66. Jabbour SA, Hardy E, Sugg J, Parikh S, Study G. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study. Diabetes Care. 2014; 37(3):740-50. doi: 10.2337/dc13-0467 PMID: 24144654
67. Ji L, Ma J, Li H, Mansfield TA, T'Joen C L, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36(1):84-100 e9. doi: 10.1016/j.clinthera.2013.11.002 PMID: 24378206
68. Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013; 15(5):432-40. doi: 10.1111/dom.12047 PMID: 23194084
69. Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014; 16(11):1102-10. doi: 10.1111/dom.12325 PMID: 24909293
70. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15(9):853-62. doi: 10.1111/dom.12127 PMID: 23668478
71. Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ. Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc. 2014; 62(7):1252-62. doi: 10.1111/jgs.12881 PMID: 24890683
72. Ljunggren O, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012; 14(11):990-9. doi: 10.1111/j.1463-1326.2012.01630.x PMID: 22651373
73. Mathieu C, Ranetti AE, Li D, Ekholm E, Cook W, Hirshberg B, et al. Randomized, double-blind, phase3 trial of triple therapy with dapagliflozin add-on to saxagliptin plus metformin in type 2 diabetes. Diabetes Care. 2015; 38(11):2009-17. doi: 10.2337/dc15-0779 PMID: 26246458
74. Matthaei S, Bowering K, Rohwedder K, Grohl A, Parikh S. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015; 38(3):365-72. doi: 10.2337/dc14-0666 PMID: 25592197
75. Matthaei S, Bowering K, Rohwedder K, Sugg J, Parikh S, Johnsson E, et al. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes. Diabetes Obes Metab. 2015; 17(11):1075-84. doi: 10.1111/dom.12543 PMID: 26212528
76. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA (1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012; 35(7):1473-8. doi: 10.2337/dc11-1693 PMID: 22446170
77. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13(10):928-38. doi: 10.1111/j.1463-1326.2011.01434.x PMID: 21672123
78. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014; 5(1):267-83. doi: 10.1007/s13300-014-0072-0 PMID: 24920277
79. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009; 32(9):1656-62. doi: 10.2337/dc09-0517 PMID: 19528367
80. Ferrannini E, Berk A, Hantel S, Pinnetti S, Hach T, Woerle HJ, et al. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care. 2013; 36(12):4015-21. doi: 10.2337/dc13-0663 PMID: 24186878
81. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013; 15(8):721-8. doi: 10.1111/dom.12081 PMID: 23398530
82. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebocontrolled trial. Diabetes Care. 2014; 37(6):1650-9. doi: 10.2337/dc13-2105 PMID: 24722494
83. Kadowaki T, Haneda M, Inagaki N, Terauchi Y, Taniguchi A, Koiwai K, et al. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebocontrolled, phase II trial. Adv Ther. 2014; 31(6):621-38. doi: 10.1007/s12325-014-0126-8 PMID: 24958326
84. Merker L, Haring HU, Christiansen AV, Roux F, Salsali A, Kim G, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med. 2015; 32(12):1555-67. doi: 10.1111/dme.12814 PMID: 26031566
85. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013; 15(12):1154-60. doi: 10.1111/dom.12185 PMID: 23906374
86. Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014; 37(7):1815-23. doi: 10.2337/dc13-3055 PMID: 24929430
87. Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015; 17(10):936-48. doi: 10.1111/dom. 12503 PMID: 26040302
88. Ross S, Thamer C, Cescutti J, Meinicke T, Woerle HJ, Broedl UC. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2015; 17(7):699-702. doi: 10. 1111/dom.12469 PMID: 25827441
89. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382 (9896):941-50. doi: 10.1016/S0140-6736(13)60683-2 PMID: 23850055
90. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015; 38(3):355-64. doi: 10.2337/dc13-2762 PMID: 25205142
91. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013; 36(9):2508-15. doi: 10.2337/ dc12-2491 PMID: 23564919
92. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012; 66(5):446-56. doi: 10.1111/j.1742-1241.2012.02911.x PMID: 22413962
93. Del Prato S, Nauck M, Duran-Garcia S, Maffei L, Rohwedder K, Theuerkauf A et al. Long-term glycaemic response and tolerability of dapagliflozin verus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015; 17(6):581-90. doi: 10.1111/ dom.12459 PMID: 25735400
94. Nauck MA, Del Prato S, Meier JJ, Duran-Garcia S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9):2015-22. doi: 10.2337/dc11-0606 PMID: 21816980
95. Nauck MA, Del Prato S, Duran-Garcia S, Rohwedder K, Langkilde AM, Sugg J, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014; 16 (11):1111-20. doi: 10.1111/dom.12327 PMID: 24919526
96. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015; 38(3):376-83. doi: 10.2337/dc14-1142 PMID: 25352655
97. DeFronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care. 2015; 38(3):384-93. doi: 10.2337/dc14-2364 PMID: 25583754
98. Lewin A, DeFronzo RA, Patel S, Liu D, Kaste R, Woerle HJ, et al. Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes. Diabetes Care. 2015; 38(3):394-402. doi: 10.2337/ dc14-2365 PMID: 25633662
99. Ridderstrale M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control. Cardiovasc Diabetol. 2013; 12:129-. doi: 10.1186/1475-2840-12-129 PMID: 24007456
100. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2:691-700. doi: 10. 1016/S2213-8587(14)70120-2 PMID: 24948511
101. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care. 2010; 33(2):442-9. doi: 10.2337/dc09-0749 PMID: 20103560
102. Ahmed MH, Husain NE, Almobarak AO. Nonalcoholic Fatty liver disease and risk of diabetes and cardiovascular disease: what is important for primary care physicians? J Family Med Prim Care. 2015; 4 (1):45-52. doi: 10.4103/2249-4863.152252 PMID: 25810989
103. Liu H, Lu HY. Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol. 2014; 20(26):8407-15. doi: 10.3748/wjg.v20.i26.8407 PMID: 25024598
104. Yilmaz Y. Liver function tests: Association with cardiovascular outcomes. World J Hepatol. 2010; 2 (4):143-5. doi: 10.4254/wjh.v2.i4.143 PMID: 21160986
105. Leiter LA, Forst T, Polidori D, Balis DA, Xie J, Sha S. Effect of canagliflozin on liver function tests in patients with type 2 diabetes. Diabetes Metab. 2016; 42(1):25-32. doi: 10.1016/j.diabet.2015.10.003 PMID: 26575250
106. Kalra S. Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology. Diabetes Ther. 2014; 5(2):355-66. doi: 10.1007/s13300-014-0089-4 PMID: 25424969
107. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol. 2006; 17(10):2886-91. doi: 10.1681/ASN.2006010063
108. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007; 13(8):599-608. doi: 10.1016/j.cardfail.2007.04.008
109. Sarnak M, Levey A, Schoolwerth A, Coresh J, Culleton B, Hamm L, et al. Kidney disease as a risk factor for development of cardiovascular disease a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation. 2003; 108(17):2154-69.
110. Storgaard H, Bagger JI, Knop FK, Vilsboll T, Rungby J. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. Basic Clin Pharmacol Toxicol. 2016; 118(2):168-70. doi: 10.1111/bcpt.12457
111. Ferrannini E, Muscelli E, Frascerra S, Baldi S, Mari A, Heise T, et al. Metabolic response to sodiumglucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest. 2014; 124(2):499-508. doi: 10.1172/jci72227